雅虎发布“缓释库疗法”对于治疗晚期胰腺癌取得良好效果
NEWPORT BEACH, CA / ACCESSWIRE / February 22, 2017 /Gregory DiRienzo, CEO of New Life Cancer Centers (www.newlifecancercenters.com
), announces its "first-of-its-kind" introduction within North America,SonataPlus, and a personalized, minimally invasive intratumoral immuno-chemo protocol for treatment of the most advanced solid cancer tumors."
Chinese clinical researcher and oncologist, Baofa Yu, has administered
minimally invasive intratumoral immuno-chemo therapy for over 20 years
to thousands of patients at Dr. Yu's cancer hospitals located outside
Beijing, China, which first became of interest to Dr. Yu while
undergoing studies in alternative drug delivery systems in the late
1990's at the University of California, San Diego, and later Salk
Institute of Biological Research, La Jolla, CA.
A clinical study published in the December 2015 issue of "Journal of
Liver Research, Disorders and Therapy" revealed that Dr Yu's protocol
(which includes a hapten component), administered before standard
surgery and/or radiation treatment, was shown to shrink and possibly
destroy pancreatic tumor(s) within weeks before commencing of any
treatment for late stage pancreatic cancers.
The concept of intratumoral drug delivery has been known for years,
with some showing clinical feasibility via significant reduction in
toxicity and tumor growth but not in pancreatic cancer. Pancreatic
cancer is in a crucial organ surrounded by vital tissues and organs,
such as the duodenum, gallbladder, portal vein, and aorta. Tumor
invasion of these organs by pancreatic cancer is most common and
generally leads to unresectability.
According to Dr. Yu, significant results presented within the study
could lead to fewer patients requiring surgically invasive tumor
removal. Moreover, by administering slow released chemo drugs together
with hapten directly into the tumor, it was shown that potential ongoing
immunology for deterring and/or hampering of pancreatic cancer
metastasis. In this study, a combination of medicines for treatment of
solid tumors was explored with dosages based upon tumor-size and
inclusion of patient-specific autologous tumor antigens to induce a
self-vaccination tumor-specific response.
The study described the results of 86 patients diagnosed with late
stage pancreatic cancer whose treatments failed standard therapy, then
treated with minimally invasive intratumoral immuno-chemo therapy. The
protocol relies primarily on an intratumoral injection procedure that
combines an approved oxidant, select chemo medicines and hapten based
immune enhancer to achieve full coagulation and necrotic efficacy within
the particular tumor mass. It was observed that coagulation within the
tumor inhibited overall blood flow and encapsulation of the injected
chemo's at higher concentrations and for significantly more days than
observed in conventional drug delivery protocols.
For Further Information:
(www.newlifecancercenters.com
)
NEW LIFE CANCER CENTERS4370 La Jolla Village Drive, Suite 980 San Diego, CA 92121 001-949-939-0050info@newlifecancercenters.com
SOURCE:New Life Cancer Centers
